Abstract |
Thionamide antithyroid drugs (ATD) are the treatment of choice for Graves' hyperthyroidism. The major drawback of ATD treatment for 1-2 years is the relapse of hyperthyroidism in about 50% of patients. Recently, it has been shown that ATD treatment for more than five years is accompanied by long-term remission in majority of patients without additional major side effects in both adults and children. Compared to radioactive iodine therapy, long-term ATD results in more favorable outcomes. This review summarizes the evidence on long-term ATD therapy regarding the remission rate of hyperthyroidism, efficacy and safety, indications and mode of therapy in patients with hyperthyroidism.
|
Authors | Fereidoun Azizi, Hengameh Abdi, Atieh Amouzegar, Ali Siamak Habibi Moeini |
Journal | Best practice & research. Clinical endocrinology & metabolism
(Best Pract Res Clin Endocrinol Metab)
Vol. 37
Issue 2
Pg. 101631
(03 2023)
ISSN: 1878-1594 [Electronic] Netherlands |
PMID | 35440398
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2022. Published by Elsevier Ltd. |
Chemical References |
- Methimazole
- Iodine Radioisotopes
- Antithyroid Agents
|
Topics |
- Adult
- Child
- Humans
- Methimazole
(adverse effects)
- Iodine Radioisotopes
(therapeutic use)
- Treatment Outcome
- Thyroid Neoplasms
(drug therapy)
- Neoplasm Recurrence, Local
- Graves Disease
(drug therapy, radiotherapy)
- Antithyroid Agents
(adverse effects)
- Hyperthyroidism
(drug therapy)
|